8th January, 2021

Dear REMAP-CAP sites,

**RE: Therapeutic Anticoagulation Domain in Moderate State patients**

I am writing to inform you of a recommendation from the DSMB of REMAP-CAP, following from the recent platform conclusion relating to the Therapeutic Anticoagulation Domain among patients in the Severe illness severity state.

As you will be aware, the REMAP-CAP DSMB have notified the ITSC that the therapeutic anticoagulation intervention reached a prespecified threshold for futility for patients in the Severe State (admitted to an Intensive Care Unit and receiving one or more qualifying organ failure supports). At the same time, the DSMB also indicated concerns regarding the overall safety of therapeutic anticoagulation for patients in the Severe State. The unanimous recommendation of the DSMB was that this domain be closed for randomisation, to patients in the Severe State. This recommendation was accepted by the ITSC.

At that time, the DSMB recommended that patients in the Moderate State (not receiving organ failure support in ICU) continue to be enrolled and randomised in the therapeutic anticoagulation domain. Following this recommendation, the ITSC requested guidance from the DSMB regarding patients who were enrolled in the Moderate state and later progressed to the Severe state.

**The recommendation of the DSMB is that patients who are enrolled in this domain while in the Moderate State should have their therapeutic anticoagulation intervention ceased if they progress to requiring organ failure support in ICU, unless there is a clinical indication to continue therapeutic anticoagulation.** This recommendation will be implemented immediately in the administration guide for this domain, and will be incorporated into the DSA with a future amendment.

If you have any questions about any of the above, please don't hesitate to contact me.

Sincerely,

Professor Steve Webb  
Chair,  
REMAP-CAP International Trial Steering Committee

Phone: +61 408 866 274  
Email: Steven.Webb@monash.edu